AstraZeneca, Rigel Pharma Treatment for Rheumatoid Arthritis Fails to Meet One

AstraZeneca, Rigel Pharma Treatment for Rheumatoid Arthritis Fails to Meet One
AstraZeneca PLC (AZN, AZN.LN) said a treatment for rheumatoid arthritis that it is partnering on with drug developer Rigel Pharmaceuticals Inc. (RIGL) failed to meet one of two main goals in a Phase IIb trial. The rheumatoid arthritis treatment, called …

Full News here – Read more on Wall Street Journal

Leave a Reply